IFG Advisory LLC reduced its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 58.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,780 shares of the medical research company’s stock after selling 5,273 shares during the quarter. IFG Advisory LLC’s holdings in Amgen were worth $1,593,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Trillium Asset Management LLC acquired a new position in shares of Amgen in the 3rd quarter worth $201,000. Bellwether Advisors LLC purchased a new stake in shares of Amgen during the third quarter valued at $2,786,000. Croban lifted its holdings in shares of Amgen by 1.0% during the third quarter. Croban now owns 4,119 shares of the medical research company’s stock valued at $1,736,000 after purchasing an additional 41 shares during the last quarter. Optas LLC lifted its holdings in shares of Amgen by 10.4% during the third quarter. Optas LLC now owns 2,006 shares of the medical research company’s stock valued at $846,000 after purchasing an additional 189 shares during the last quarter. Finally, Silver Oak Advisory Group Inc. acquired a new position in shares of Amgen in the 3rd quarter valued at $226,000. 76.50% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on AMGN. Sanford C. Bernstein increased their price target on Amgen from $345.00 to $400.00 and gave the company a “market perform” rating in a research report on Wednesday, November 4th. Robert W. Baird boosted their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a report on Wednesday, August 5th. Bank of America upped their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday, October 18th. Finally, Leerink Partners raised their target price on shares of Amgen from $395.00 to $464.00 and gave the stock a “market perform” rating in a report on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $425.69.
Read Our Latest Analysis on Amgen
Amgen Price Performance
Shares of NASDAQ:AMGN opened at $462.32 on Tuesday. The company’s fifty day moving average is $425.81 and its two-hundred day moving average is $381.77. The company has a market cap of $250.07 billion, a P/E ratio of 26.82, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. Amgen Inc. has a 12-month low of $312.39 and a 12-month high of $483.99. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. During the same quarter last year, the firm posted $5.64 earnings per share. Amgen’s revenue was up 8.5% compared to the same quarter last year. Equities analysts expect that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.
Amgen Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s payout ratio is 58.47%.
About Amgen
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Recommended Stories
- Five stocks we like better than Amgen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
